A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer

• Autori principali: Thomas G. Frazier (Autore), Kevin R. Fox (Autore), J. Stanley Smith (Autore), Christine Laronga (Autore), Anita McSwain (Autore), Devchand Paul (Autore), Michael Schultz (Autore), Joseph Stilwill (Autore), Christine Teal (Autore), Tracey Weisberg (Autore), Judith F. Vacchino (Autore), Amy P. Sing (Autore), Dasha Cherepanov (Autore), Wendy Hsiao (Autore), Eunice Chang (Autore), Michael S. Broder (Autore)
• Natura: Libro
• Pubblicazione: MDPI AG, 2015-03-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

To assess clinical utility of the 21-gene assay (Oncotype DX® Recurrence Score®), we determined whether women with HER2(−)/ER+ pN1mi breast cancer with low (<18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion than those with high scores (≥31). This was a multicent...